Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Immunotherapy in Follicular Lymphoma
NCT03636503Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of utomilumab, avelumab and ivuxolimab in follicular lymphoma (FL) (7 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Recommended Phase 2 Dosing at 6 months and Complete Response Per Lugano Criteria at 6 months. Started Oct 2018; status: terminated.
02
Drugs
utomilumabavelumabivuxolimab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03636503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636503.